Stock Hero Advertisement
Home > Boards > US Listed > Biotechs >

Opko Health Inc (OPK)

Add OPK Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator stonsetr, now invest, ntropy
Search This Board:
Last Post: 4/28/2015 10:16:31 AM - Followers: 130 - Board type: Free - Posts Today: 1
Opko Health Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD Wednesday July 11, 8:00 am ET -Trial Designed to Compare Efficacy of Bevasiranib Administered Every 8 Weeks or 12 Weeks with Lucentis(R) Administered Every 4 Weeks- -Represents First-Ever Phase 3 Pivotal Trial of an RNAi Therapeutic- MIAMI, July 11 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced the initiation of the Phase 3 COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet age-related macular degeneration (wet AMD.) The multi-national COBALT study is currently open and enrolling patients. The trial will include more than 330 wet AMD patients and will assess whether bevasiranib administered every 8 or 12 weeks is safe and has equivalent efficacy in preventing vision loss as Genentech's Lucentis® administered every four weeks. ADVERTISEMENT Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the genes that produce vascular endothelial growth factor (VEGF), believed to be largely responsible for the vision loss of wet AMD. Bevasiranib is the first therapy based on the Nobel Prize-winning RNA interference (RNAi) technology to advance to Phase 3 clinical trials. "This first-ever Phase 3 trial of an agent based on RNAi technology is an important milestone in this new field. We are proud of the ability demonstrated by our clinical group to have successfully moved this innovative compound through development rapidly and cost effectively," said Philip Frost, M.D., Chairman and CEO of Opko Health. "Currently patients with wet AMD undergo intravitreal injections every four weeks to achieve the vision- preserving benefits of Lucentis, so the potential ability of bevasiranib to achieve similar results while requiring less frequent injections would be an important benefit for these patients who often have limited mobility." "Bevasiranib's demonstrated safety profile, its ability to inhibit the growth of the retinal lesions associated with wet AMD and its potential for prolonged duration are a promising foundation for this pivotal trial," said Lawrence Singerman M.D., founder and Executive Secretary of the Macula Society, Clinical Professor of Ophthalmology at Case University and a Principal Investigator for the Phase 3 study. "Bevasiranib's potential to serve as a long-term maintenance therapy for wet AMD could provide important benefits to patients, and I look forward to helping to assess its utility in this groundbreaking study." "We are very pleased at the enthusiastic reception the COBALT trial has received from retinal centers around the globe," said Denis O'Shaughnessy, Ph.D., Senior Vice President of Clinical Development at Opko. "Retinal physicians are keenly aware of the burden that frequent drug injections places on elderly patients and their families, and they are eager to help test an innovative new approach that has the potential to significantly reduce that burden while preserving patients' vision." About Wet AMD Wet age-related macular degeneration is the leading cause of irreversible vision loss in the developed world and its incidence is growing rapidly. Advanced age is the main risk factor for wet AMD, and it is expected to become an increasingly common condition as the population grows older. An estimated 1.65 million Americans have wet AMD today and an estimated 11 million people worldwide will have AMD by 2013. Until recently, treatments for wet AMD were of limited efficacy. In the search for more effective treatments, researchers targeted VEGF, shown to be a key cause of the excess growth and leakiness of ocular blood vessels that result in loss of vision in these patients. Current VEGF antagonists, such as Lucentis, slow this vision loss, but require injections into the eye every four weeks, a particular issue for elderly patients who often have limited mobility. Opko Health, Inc. Announces Early Termination of Hart-Scott-Rodino Waiting Period for Proposed Purchase of Shares by Dr. Phillip Frost Thursday July 12, 8:00 am ET MIAMI July 12 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced that that the U.S. Department of Justice has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the potential acquisition of additional shares of Opko Health common stock by Dr. Phillip Frost, CEO and Chairman of Opko. Dr. Frost has requested clearance to purchase additional shares of Opko Health common stock, which this action by the Justice Department now makes feasible.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
Option Chain for OPK
OPK News: Statement of Changes in Beneficial Ownership (4) 06:10 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 04/27/2015 06:30:39 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 04/22/2015 06:51:59 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 04/20/2015 06:45:23 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 04/17/2015 07:23:52 AM
News News Alert: Statement of Changes in Beneficial Ownership (4) 04/28/2015 06:10:01 AM
#3215  Sticky Note Pfizer Partners With Young Little Known Biotech For tomsylver 12/18/14 09:06:21 AM
#3661   Frost is buying right now... But who is selling?? PennyStalker 04/28/15 10:16:31 AM
#3660   in Pre market... OPK at 15.10 +27..... now invest 04/27/15 08:38:06 AM
#3659   Good sign for tomorrow game7alcs 04/26/15 05:52:44 PM
#3658   Opko Health Rose 3.69% For The Biggest Gain WiseFool 04/26/15 04:45:50 PM
#3657   Yea I agree that's a possibility. Hopefully the game7alcs 04/25/15 03:59:17 PM
#3656   87,000 and 25,000 shares traded AH on Friday... PennyStalker 04/25/15 02:39:38 PM
#3655   What size trades were they? game7alcs 04/25/15 11:13:38 AM
#3654   Those were some big AH trades Friday. BigWorm129 04/25/15 08:43:06 AM
#3653   TESARO Launches Campaign to Raise Awareness of Chemotherapy-Induced tomsylver 04/24/15 01:12:23 AM
#3652   TESARO Announces Participation at Three Investor Conferences WALTHAM, Mass., tomsylver 04/22/15 11:16:22 PM
#3651   Opko / Pfizer Partnership Ready to Flourish WiseFool 04/22/15 04:15:40 PM
#3650   OPKO CEO Dr. Phillip Frost, MD "the Warren WiseFool 04/22/15 03:39:36 PM
#3649   OPKO Announces Publication of ProtecT Study Using Kallikrein tomsylver 04/21/15 11:22:30 AM
#3648   Clinical Oncology News Opko 4Kscore WiseFool 04/20/15 03:43:20 PM
#3647   Hey.... I am in for the ride... now invest 04/19/15 10:54:06 PM
#3646   I have been accumulating small amounts too. We game7alcs 04/19/15 09:12:12 AM
#3645   I decided to buy a couple hundred more.... now invest 04/18/15 10:53:27 AM
#3644   It was a great day to buy as ntropy 04/17/15 04:10:55 PM
#3643   Frost took a few days off. Back at it PennyStalker 04/17/15 07:37:30 AM
#3642   I Love The Sound Of That... Snowslide 04/16/15 06:19:17 PM
#3641   Nice.... now invest 04/15/15 09:57:39 PM
#3640   Nice find! Are you related to the company in PennyStalker 04/15/15 07:41:57 PM
#3639   Sound Clip from April 14, 2015 Mad Money WiseFool 04/15/15 06:47:06 PM
#3638   Opko Health Assigned Patent for Asthma Related Disorders WiseFool 04/15/15 03:31:16 PM
#3637   Frost is truly building a HUGE company... I now invest 04/15/15 09:46:19 AM
#3636 WiseFool 04/14/15 07:12:08 PM
#3635   Nice bounce off the 50. stonsetr 04/14/15 11:23:42 AM
#3634   MA(50) is moving up fast... Will we stay above PennyStalker 04/09/15 12:01:43 PM
#3633 WiseFool 04/08/15 03:33:53 PM
#3632   MicroCap Daily on MabVax Private Placement Led by WiseFool 04/07/15 03:47:14 PM
#3631   Opko 4Kscore AUA Citation Updates 'High Degree Of WiseFool 04/06/15 07:20:27 PM
#3630   CORAL GABLES, FL / ACCESSWIRE / April 6, tomsylver 04/06/15 03:39:34 PM
#3629   Notice Chromadex, Cocrystal and Opko DOUBLED this year rtraster 04/06/15 08:56:40 AM
#3628   Announces Closing of Financing SAN DIEGO, April 6, 2015 tomsylver 04/06/15 08:16:31 AM
#3627   "One of these days Alice" stonsetr 04/03/15 03:54:25 PM
#3626   They just keep making progress! now invest 04/03/15 03:31:32 PM
#3625 N WiseFool 04/03/15 09:26:29 AM
#3624   The filling for Rayaldee should be in Q1. tomsylver 04/02/15 11:53:33 AM
#3623   ?? tomsylver 03/30/15 02:44:29 PM
#3622   Tomorrow NDA-Filling for Rayaldee tomsylver 03/30/15 02:44:12 PM
#3621   Transcript taken from opkodd site. Ceo of Renal WiseFool 03/28/15 10:07:31 AM
#3620   Phase 3 Data Supporting Rayaldee(TM) As a Treatment tomsylver 03/27/15 09:17:22 AM
#3619   Arizona Urology Specialists Use Opko 4Kscore WiseFool 03/26/15 03:44:43 PM
#3618   Barrington Research Assumes Coverage On Opko Health WiseFool 03/26/15 03:23:26 PM
#3617   He is very steady in his buys. Price game7alcs 03/26/15 09:28:02 AM
#3616   Yes, I see at $14.15 pps. I feel joe_techi 03/26/15 09:26:53 AM
#3615   Frost purchased another $500,000 worth yesterday PennyStalker 03/26/15 09:19:55 AM
#3614   A selloff was being called for this week game7alcs 03/25/15 02:52:37 PM
#3613   Interesting, if you simultaneously display today's charts for joe_techi 03/25/15 02:42:18 PM
#3612   It's biotech in general today game7alcs 03/25/15 02:00:08 PM